Scholarlink

Background <p>Remimazolam is a short-acting benzodiazepine anesthetic recommended for continuous infusion during anesthesia induction. However, the safety and efficacy of single bolus dose administration remain under investigation. This study compared continuous infusion with single bolus dose administration and assessed the safety of a single bolus dose administration.</p> Methods <p>The participants were randomly assigned into three groups based on the method of remimazolam administration the day before surgery: (1) continuous infusion group (continuous infusion at 12&#xa0;mg/kg/h), (2) single bolus dose administration of 0.1 group (single administration of 0.1&#xa0;mg/kg), or (3) single bolus dose administration of 0.2 group (single administration of 0.2&#xa0;mg/kg). The time between drug administration and loss of consciousness was determined, and hemodynamic monitoring was performed.</p> Results <p>67 patients (continuous infusion group (<i>n</i> = 22), single bolus dose administration of 0.1 group (<i>n</i> = 22), and single bolus dose administration of 0.2 group (<i>n</i> = 23)) were included in the study. The different times to loss of consciousness were 88.2 ± 16.2&#xa0;s, 59.5 ± 31.5&#xa0;s, and 42.6 ± 11.4&#xa0;s in the continuous infusion group, single bolus dose administration of 0.1 group, and single bolus dose administration of 0.2 group, respectively. No significant differences were observed in the incidence of adverse events between the groups. The results are presented as mean ± standard deviation (SD).</p> Conclusions <p>Single-dose remimazolam is a safe method for anesthesia induction, resulting in shorter time to loss of consciousness compared with continuous infusion, while maintaining a similar incidence of adverse events.</p> Trial registration <p>jRCTs061230049, registered on 17/08/2023.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Comparison between single bolus dose administration and continuous infusion of remimazolam for general anesthesia induction in non-cardiac surgery: a single-center prospective randomized controlled trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月2日

查看全文
  • Tsuyoshi Ikeda,
  • Hirotsugu Miyoshi,
  • Kenshiro Kido,
  • Ayako Sumii,
  • Sachiko Otsuki,
  • Takahiro Kato,
  • Ryuji Nakamura,
  • Soshi Narasaki,
  • Yasuo M. Tsutsumi

摘要

Background

Remimazolam is a short-acting benzodiazepine anesthetic recommended for continuous infusion during anesthesia induction. However, the safety and efficacy of single bolus dose administration remain under investigation. This study compared continuous infusion with single bolus dose administration and assessed the safety of a single bolus dose administration.

Methods

The participants were randomly assigned into three groups based on the method of remimazolam administration the day before surgery: (1) continuous infusion group (continuous infusion at 12 mg/kg/h), (2) single bolus dose administration of 0.1 group (single administration of 0.1 mg/kg), or (3) single bolus dose administration of 0.2 group (single administration of 0.2 mg/kg). The time between drug administration and loss of consciousness was determined, and hemodynamic monitoring was performed.

Results

67 patients (continuous infusion group (n = 22), single bolus dose administration of 0.1 group (n = 22), and single bolus dose administration of 0.2 group (n = 23)) were included in the study. The different times to loss of consciousness were 88.2 ± 16.2 s, 59.5 ± 31.5 s, and 42.6 ± 11.4 s in the continuous infusion group, single bolus dose administration of 0.1 group, and single bolus dose administration of 0.2 group, respectively. No significant differences were observed in the incidence of adverse events between the groups. The results are presented as mean ± standard deviation (SD).

Conclusions

Single-dose remimazolam is a safe method for anesthesia induction, resulting in shorter time to loss of consciousness compared with continuous infusion, while maintaining a similar incidence of adverse events.

Trial registration

jRCTs061230049, registered on 17/08/2023.